{"entity":{"id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","aka":[],"tldr":"A phase 3 trial of IgPro20 in advanced solid tumours, run by CSL Behring, now recruiting.","summary":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies is a phase 3 interventional study registered as NCT07648264 by CSL Behring, with 63 participants planned, started 2026-09-11 and due to reach its primary completion in 2029-03-13. Interventions recorded: IgPro20.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07648264","url":"https://clinicaltrials.gov/study/NCT07648264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["csl"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07648264","phase":"3","setting":"A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","sponsor":"CSL Behring","enrolled":63,"outcomes":[]},"route":"/trials/nct07648264/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/"}]}}